1,721,140 research outputs found
Anti-PCSK9 treatment: Is ultra-low LDL always good?
Anti-pcsk9 (proprotein convertase subtilisin kexin 9) monoclonal antibodies (Mab) are novel, potent lipid-lowering drugs. They demonstrated to improve the lipid profile in high cardiovascular risk patients. Anti-pcsk9 Mab inhibit the targeted LDL-receptor degradation induced by pcsk9 protein and are able to reduce LDL cholesterol (LDL-C) levels on top of conventional lipid-lowering therapy.Though these drugs proved to be very safe in the short term, little is known about the possible long term effects, due to the short period of their marketing. The genetic low-cholesterol syndromes (LCS) represent the natural models of the lipid-lowering anti-PCSK9 therapy, and a valuable opportunity to predict the long term effects of these drugs. By looking at the clinical features of such models we could be able to foresee possible drug-induced side effects. In the present review the correspondences and discordances between the side effects of anti-pcsk9 therapy and the corresponding LCS models will be examined in the attempt to forecast possible long term consequences of these novel lipid lowering agents
EFFECTIVENESS AND SAFETY OF LOMITAPIDE IN A PATIENT WITH FAMILIAL CHYLOMICRONEMIA SYNDROME
Hepatic lipase and lipoprotein lipase are affected by combined estrogen+progestin hormone therapy
Dietary strategy for prevention and management of dyslipidemia: International guidelines
Primary prevention of cardiovascular disease
should begin with a detailed metabolic study of our patients
who must follow a nutritional therapy. Recently, new
guidelines ESC/EAS 2011 on the treatment of dyslipidemia
have been drawn up, according to which it is possible to
arrive at desirable values of cholesterol and triglycerides
with a synergy between drug treatment and adequate diet
therapy. At this time, Mediterranean diet has been undergoing
a radical transformation: there is hyperalimentation of
the Mediterranean diet in all its components. The effectiveness
of the Mediterranean diet on the reduction of lipids has
been demonstrated, and the problem is how to implement this
diet in the general population and dyslipidemic patients.
Certainly, awareness, education of their nutritional status,
suitable food and portions can increase adherence to diet
Accumulo di VLDL/IDL contenenti ApoE in maschi normolipemici con cardiopatia ischemica precoce
Chilomicronemia transitoria causa di diabete di tipo I in assenza di markers umorali di autoimmunità in una bambina di nove anni
Accumulation of ApoE-containing triglyceride-rich lipoproteins in normolipidemic men with premature coronary artery disease
- …
